Teriparatide

Generic Name
Teriparatide
Brand Names
Forsteo, Forteo, Movymia, Kauliv, Sondelbay, Teriparatide Sun, Terrosa, Livogiva
Drug Type
Biotech
Chemical Formula
-
CAS Number
52232-67-4
Unique Ingredient Identifier
10T9CSU89I
Background

Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic th...

Indication

Teriparatide is indicated:

Associated Conditions
Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Primary Osteoporosis
Associated Therapies
-
Clinical Trials
Related News

Impact of Parathyroid Hormone (PTH) on Osseous Cavity

First Posted Date
2006-01-16
Last Posted Date
2009-10-07
Lead Sponsor
University of Michigan
Target Recruit Count
40
Registration Number
NCT00277706
Locations
🇺🇸

Michigan Center for Oral Health Research, Ann Arbor, Michigan, United States

Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis

Phase 4
Completed
Conditions
Osteoporosis
Interventions
Drug: teriparatide
First Posted Date
2005-11-29
Last Posted Date
2010-08-11
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
12
Registration Number
NCT00259298
Locations
🇬🇧

For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, London, United Kingdom

Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial

Phase 4
Completed
Conditions
Postmenopausal Osteoporosis
First Posted Date
2005-10-17
Last Posted Date
2007-06-12
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
73
Registration Number
NCT00239629
Locations
🇪🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain

Teriparatide Use in Hip Replaced Subjects

Phase 3
Completed
Conditions
Osteoporosis
First Posted Date
2005-09-19
Last Posted Date
2007-01-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
60
Registration Number
NCT00191321
Locations
🇮🇹

For additional information regarding investigative sites for thsi trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Udine, Italy

Compliance and Acceptance of Teriparatide Injection in Severely Osteoporotic Patients

Phase 3
Completed
Conditions
Osteoporosis
First Posted Date
2005-09-19
Last Posted Date
2007-01-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
120
Registration Number
NCT00191802
Locations
🇨🇦

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saskatoon, Saskatchewan, Canada

Bone Effects of Teriparatide Following Alendronate

Phase 3
Completed
Conditions
Osteoporosis
First Posted Date
2005-09-19
Last Posted Date
2007-01-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
66
Registration Number
NCT00191893
Locations
🇨🇿

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Praha, Czech Republic

2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis

Phase 4
Completed
Conditions
Osteoporosis, Postmenopausal
First Posted Date
2005-09-19
Last Posted Date
2007-07-16
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
810
Registration Number
NCT00191425
Locations
🇩🇪

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Pyrmont, Germany

Clinical Trial of Teriparatide in Japan

Phase 2
Completed
Conditions
Osteoporosis
First Posted Date
2005-09-19
Last Posted Date
2007-11-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
160
Registration Number
NCT00191867
Locations
🇯🇵

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tokyo, Japan

Effects of Teriparatide on Distal Radius Fracture Healing

Phase 2
Completed
Conditions
Colles' Fracture
First Posted Date
2005-09-19
Last Posted Date
2007-10-12
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
105
Registration Number
NCT00190944
Locations
🇸🇪

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Linkoping, Sweden

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

Phase 4
Completed
Conditions
Postmenopausal Osteoporosis
First Posted Date
2004-03-19
Last Posted Date
2007-05-25
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
200
Registration Number
NCT00079924
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tulsa, Oklahoma, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy